Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Galimberti V, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan M, Coates A, Gelber R, Goldhirsch A, Littlejohn D, Taffurelli M, Cole B, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 2018
Sep 5, 2018
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
Sep 5, 2018
Lancet Oncol 2018
Galimberti Viviana, Knauer Michael, Tondini Carlo, Di Leo Angelo, Colleoni Marco, Regan Meredith M, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Littlejohn David, Taffurelli Mario, Cole Bernard F, Viale Giuseppe, Veronesi Paolo, Vicini Elisa, Intra Mattia, Mazzarol Giovanni, Massarut Samuele, Zgajnar Janez, International Breast Cancer Study Group Trial 23-01
more
